Castle Creek Biosciences, Llc.
Clinical trials sponsored by Castle Creek Biosciences, Llc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy mends wounds in rare 'butterfly skin' disease Results expected Sep 2027 (estimated)
-
Gene therapy heals wounds in rare skin disease?
Disease control OngoingThis phase 3 trial tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa, a rare disease that causes fragile skin and painful blisters. The therapy uses the patient's own skin cells, genetically corrected to produce collagen, and injects t…
Phase 3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gene therapy mends wounds in rare 'butterfly skin' disease
Disease control OngoingThis study tests a treatment called D-Fi, made from a person's own skin cells that are genetically modified to produce a missing protein. It aims to see if injecting these cells into wounds helps them close completely compared to standard care alone. The trial includes 32 childre…
Phase 3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC